These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

856 related articles for article (PubMed ID: 16732175)

  • 1. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease.
    Ringdén O; Uzunel M; Rasmusson I; Remberger M; Sundberg B; Lönnies H; Marschall HU; Dlugosz A; Szakos A; Hassan Z; Omazic B; Aschan J; Barkholt L; Le Blanc K
    Transplantation; 2006 May; 81(10):1390-7. PubMed ID: 16732175
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Favorable response to human adipose tissue-derived mesenchymal stem cells in steroid-refractory acute graft-versus-host disease.
    Fang B; Song Y; Liao L; Zhang Y; Zhao RC
    Transplant Proc; 2007 Dec; 39(10):3358-62. PubMed ID: 18089385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of refractory acute GVHD with third-party MSC expanded in platelet lysate-containing medium.
    von Bonin M; Stölzel F; Goedecke A; Richter K; Wuschek N; Hölig K; Platzbecker U; Illmer T; Schaich M; Schetelig J; Kiani A; Ordemann R; Ehninger G; Schmitz M; Bornhäuser M
    Bone Marrow Transplant; 2009 Feb; 43(3):245-51. PubMed ID: 18820709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Results of a pilot study on the use of third-party donor mesenchymal stromal cells in cord blood transplantation in adults.
    Gonzalo-Daganzo R; Regidor C; Martín-Donaire T; Rico MA; Bautista G; Krsnik I; Forés R; Ojeda E; Sanjuán I; García-Marco JA; Navarro B; Gil S; Sánchez R; Panadero N; Gutiérrez Y; García-Berciano M; Pérez N; Millán I; Cabrera R; Fernández MN
    Cytotherapy; 2009; 11(3):278-88. PubMed ID: 19308773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients.
    Lazarus HM; Koc ON; Devine SM; Curtin P; Maziarz RT; Holland HK; Shpall EJ; McCarthy P; Atkinson K; Cooper BW; Gerson SL; Laughlin MJ; Loberiza FR; Moseley AB; Bacigalupo A
    Biol Blood Marrow Transplant; 2005 May; 11(5):389-98. PubMed ID: 15846293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of multipotent mesenchymal stromal cells in pediatric patients following allogeneic stem cell transplantation.
    Müller I; Kordowich S; Holzwarth C; Isensee G; Lang P; Neunhoeffer F; Dominici M; Greil J; Handgretinger R
    Blood Cells Mol Dis; 2008; 40(1):25-32. PubMed ID: 17869550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of severe steroid refractory acute graft-versus-host disease with infliximab, a chimeric human/mouse antiTNFalpha antibody.
    Kobbe G; Schneider P; Rohr U; Fenk R; Neumann F; Aivado M; Dietze L; Kronenwett R; Hünerlitürkoglu A; Haas R
    Bone Marrow Transplant; 2001 Jul; 28(1):47-9. PubMed ID: 11498743
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet-lysate-expanded mesenchymal stromal cells as a salvage therapy for severe resistant graft-versus-host disease in a pediatric population.
    Lucchini G; Introna M; Dander E; Rovelli A; Balduzzi A; Bonanomi S; Salvadè A; Capelli C; Belotti D; Gaipa G; Perseghin P; Vinci P; Lanino E; Chiusolo P; Orofino MG; Marktel S; Golay J; Rambaldi A; Biondi A; D'Amico G; Biagi E
    Biol Blood Marrow Transplant; 2010 Sep; 16(9):1293-301. PubMed ID: 20350611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Co-infusion of donor bone marrow with host mesenchymal stem cells treats GVHD and promotes vascularized skin allograft survival in rats.
    Aksu AE; Horibe E; Sacks J; Ikeguchi R; Breitinger J; Scozio M; Unadkat J; Feili-Hariri M
    Clin Immunol; 2008 Jun; 127(3):348-58. PubMed ID: 18387852
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study.
    Le Blanc K; Frassoni F; Ball L; Locatelli F; Roelofs H; Lewis I; Lanino E; Sundberg B; Bernardo ME; Remberger M; Dini G; Egeler RM; Bacigalupo A; Fibbe W; Ringdén O;
    Lancet; 2008 May; 371(9624):1579-86. PubMed ID: 18468541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Mesenchymal stem cells for treatment of steroid-resistant chronic graft-versus-host disease].
    Zhang LS; Liu QF; Huang K; Zhang Y; Fan ZP; Huang SL
    Zhonghua Nei Ke Za Zhi; 2009 Jul; 48(7):542-6. PubMed ID: 19957792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful prevention of acute graft-versus-host disease using low-dose antithymocyte globulin after mismatched, unrelated, hematopoietic stem cell transplantation for acute myelogenous leukemia.
    Kim HJ; Min WS; Cho BS; Eom KS; Kim YJ; Min CK; Lee S; Cho SG; Jin JY; Lee JW; Kim CC
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):704-17. PubMed ID: 19450755
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bone marrow-derived mesenchymal stem cells decrease acute graft-versus-host disease after allogeneic hematopoietic stem cells transplantation.
    Tian Y; Deng YB; Huang YJ; Wang Y
    Immunol Invest; 2008; 37(1):29-42. PubMed ID: 18214798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
    Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK
    Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal™) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study.
    Prasad VK; Lucas KG; Kleiner GI; Talano JA; Jacobsohn D; Broadwater G; Monroy R; Kurtzberg J
    Biol Blood Marrow Transplant; 2011 Apr; 17(4):534-41. PubMed ID: 20457269
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extracorporeal photopheresis therapy in the management of steroid-refractory or steroid-dependent cutaneous chronic graft-versus-host disease after allogeneic stem cell transplantation: feasibility and results.
    Apisarnthanarax N; Donato M; Körbling M; Couriel D; Gajewski J; Giralt S; Khouri I; Hosing C; Champlin R; Duvic M; Anderlini P
    Bone Marrow Transplant; 2003 Mar; 31(6):459-65. PubMed ID: 12665841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infliximab treatment for steroid-refractory acute graft-versus-host disease.
    Patriarca F; Sperotto A; Damiani D; Morreale G; Bonifazi F; Olivieri A; Ciceri F; Milone G; Cesaro S; Bandini G; Dini G; Corradini P; Fanin R
    Haematologica; 2004 Nov; 89(11):1352-9. PubMed ID: 15531458
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risk factors for acute graft-versus-host disease grades II-IV after reduced intensity conditioning allogeneic stem cell transplantation with unrelated donors: a single centre study.
    Remberger M; Mattsson J; Hassan Z; Karlsson N; LeBlanc K; Omazic B; Okas M; Sairafi D; Ringdén O
    Bone Marrow Transplant; 2008 Feb; 41(4):399-405. PubMed ID: 17982493
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of extracorporeal photoimmunotherapy (ECP) on serum TNF-a level in chronic graft versus host disease (GvHD).
    Ayyildiz E; Arslan O; Topçuoğlu P; Arat M; Dalva K; Soydan EA; Tol M; Ilhan O
    Transfus Apher Sci; 2007 Feb; 36(1):79-85. PubMed ID: 17234454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 43.